ClinicalTrials.gg
RecruitingNCT07209202FIGUpdated Mar 6, 2026

Fructose Intestinal Gluconeogenesis

An interventional study of High fructose meal and Low fructose meal in Healthy Participants and Obese But Otherwise Healthy Participants, sponsored by Touro University, California. Recruiting at 1 site in United States. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Touro University, California · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.

Read the detailed description

Qualified participants will undergo a sugar tolerance test at baseline and then randomized to undergo four separate outpatient tracer/feeding studies in a crossover fashion. After an overnight fast, a six-hour fed tracer study will be initiated, during which participants will consume liquid meals containing stable isotopes at regular intervals and receive other isotopes intravenously. Meal composition will differ only by fructose content (High vs. Low) and tracer (oral vs. intravenous 13C-labeled fructose). Blood and urine samples will be collected frequently throughout the study. Each visit will be performed approximately three weeks apart. Vital signs and anthropometrics will be measured at each clinic visit.

02

Conditions studied

  • Healthy Participants
  • Obese But Otherwise Healthy Participants

Keywords

  • Fructose
  • Sugar
03

In context

Lead sponsor

Touro University, California is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 30 to 38 kg/m2 (obese group) or BMI 19 to 25 kg/m2 (lean group)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation within the past six months;
  • Type 1 or 2 diabetes mellitus (including fasting glucose ≥126 mg/dL, HgbA1c ≥6.5%);
  • History of liver disease or and ALT 2x above the ;
  • Fasting triglyceride > 300 mg/dl; total cholesterol levels above the 95th percentile for age and sex;
  • (Hgb) \<12.5g/d or hematocrit\<3x Hgb value;
  • Report of or or C infection;
  • History of cancer, other than basal cell or squamous cell carcinoma or kidney disease stage 3 or higher or patients currently on dialysis;
  • Use of any anti-diabetic medications or hypolipidemic agents in the past six months;
  • History of surgical procedure for obesity;
  • Change in body weight >5% in the past six months (by self-report);
  • History of other conditions known to affect insulin sensitivity and lipid metabolism (e.g., polycystic ovary syndrome), history of galactosemia, hereditary fructose intolerance, or who test positive for fructose malabsorption at screening;
  • Known intolerance to acetaminophen.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    High fructose meals, oral 13C fructose

    Liquid meals will be fed, containing 55% total carbohydrate (16% fructose), 30% fat, 15% protein, and a tracer amount of 13C fructose.

    Other: High fructose meal · Other: 13C labeled fructose, oral

  • Experimental
    High Fructose Meals, IV 13C Fructose

    Liquid meals will be fed, containing 55% total carbohydrate (16% fructose), 30% fat, 15% protein. A tracer amount of 13C fructose will be administered intravenously.

    Other: High fructose meal · Other: 13C labeled fructose, intravenous

  • Experimental
    Low fructose meals, oral fructose tracer

    Liquid meals will be fed, containing 55% total carbohydrate (6% fructose), 30% fat, 15% protein, and a tracer amount of 13C fructose.

    Other: Low fructose meal · Other: 13C labeled fructose, oral

  • Experimental
    Low fructose meals, IV 13C fructose tracer

    Liquid meals will be fed, containing 55% total carbohydrate (6% fructose), 30% fat, 15% protein. A tracer amount of 13C fructose will be administered intravenously.

    Other: Low fructose meal · Other: 13C labeled fructose, intravenous

Interventions

  • OtherHigh fructose meal

    Liquid meals containing 55% total carbohydrate (16% fructose), 30% fat, 15% protein.

  • OtherLow fructose meal

    55% total carbohydrate (6% fructose), 30% fat, 15% protein.

  • Other13C labeled fructose, oral

    Tracer amount of 13C labeled fructose administered orally in the meals.

  • Other13C labeled fructose, intravenous

    Tracer amount of 13C fructose administered intravenously

06

What researchers measure

Primary outcomes

  1. Fru-GNG

    Total amount of fructose converted to glucose

    Time frame: 6 hours

  2. Fru-hGNG

    Amount of fructose converted to glucose in the liver

    Time frame: 6 hours

  3. Fru-iGNG

    Amount of fructose converted to glucose in the intestine

    Time frame: 6 hours

  4. De novo lipogenesis (DNL)

    Percent of newly synthesized palmitate

    Time frame: 6 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified clinical and laboratory data set will be made available upon request to academic investigators.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Study data will be made available for at least 5 years from publication of the primary manuscript.

Access criteria: Academic investigators may request data and supporting information upon request to the PI.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jun 2030, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Oct 6, 2025
StartActual
Mar 2, 2026
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07209202
Lead sponsor
Touro University, California
Responsible party
Jean-marc Schwarz (Professor, Touro University, California) — Principal investigator
First posted
Oct 6, 2025
Start date
Mar 2, 2026
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Mar 6, 2026

Study contacts

Sally Chiu, PhD
Contact
schiu2@touro.edu
707-638-5404
Lisa Johnson, RN
Contact
ljohnson19@touro.edu
Jean-Marc Schwarz, PhD
principal investigator · Touro University, California
Grace M Jones, PhD
principal investigator · Touro University, California

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion